
3696.HK+36.16%16.7%

ARQT+56.90%16.7%

HALO+50.61%16.7%

OBIO+110.20%16.7%

VCEL+15.26%16.7%

WVE-47.88%16.7%
As of Aug 24, 2026, 4:53 AM ET
MedTech Long '25: Adv Bio Therapeutics & Regenerative Med Constituents
Arcutis Biotherapeutics, Inc.ARQT | 16.7% | -1.07% | -4.38% | -8.30% | -6.63% | -13.64% | -7.01% | 51.08% | 155.14% | 19.26% | 56.90% | $3.14B |
Halozyme Therapeutics, Inc.HALO | 16.7% | 1.93% | 5.41% | 32.03% | 31.05% | 60.73% | 55.57% | 71.64% | 72.46% | 165.77% | 50.61% | $12.83B |
InSilico Medicine Cayman TopCo3696.HK | 16.7% | -7.29% | -14.62% | -12.92% | -10.33% | 9.48% | -34.01% | 35.63% | 34.75% | 34.75% | 36.16% | $3.00B |
Orchestra BioMed Holdings, Inc.OBIO | 16.7% | -1.29% | 21.82% | 43.32% | 34.67% | 29.16% | 22.37% | 52.27% | -19.03% | -45.11% | 110.20% | $321.0M |
Vericel CorporationVCEL | 16.7% | 1.35% | -3.77% | -5.26% | -7.14% | 18.52% | 19.62% | -3.68% | -13.41% | -18.72% | 15.26% | $2.19B |
Wave Life Sciences Ltd.WVE | 16.7% | 0.76% | 4.75% | -8.95% | -3.99% | -68.88% | -62.02% | -30.12% | -7.84% | -12.13% | -47.88% | $1.04B |
| Theme return | — | -0.93% | 1.54% | 7.85% | 6.56% | 6.95% | -0.77% | 43.89% | 62.30% | 124.61% | 42.22% | — |
| Average | 16.7% | -0.93% | 1.54% | 6.65% | 6.27% | 5.89% | -0.91% | 29.47% | 37.01% | 23.97% | 36.88% | $3.75B |
| Median | 16.7% | -0.16% | 0.49% | -6.78% | -5.31% | 14.00% | 6.31% | 43.36% | 13.46% | 3.57% | 43.39% | $2.59B |
| Std Dev | 0.0% | 3.08% | 11.26% | 22.29% | 18.92% | 40.19% | 38.77% | 35.24% | 61.79% | 68.49% | 47.64% | $4.18B |
| Min | 16.7% | -7.29% | -14.62% | -12.92% | -10.33% | -68.88% | -62.02% | -30.12% | -19.03% | -45.11% | -47.88% | $321.0M |
| Max | 16.7% | 1.93% | 21.82% | 43.32% | 34.67% | 60.73% | 55.57% | 71.64% | 155.14% | 165.77% | 110.20% | $12.83B |
| % Positive Tickers | 50.00% | 50.00% | 33.33% | 33.33% | 66.67% | 50.00% | 66.67% | 50.00% | 50.00% | 83.33% |
About this theme
MedTech Long '25: Adv Bio Therapeutics & Regenerative Med tracks 6 publicly listed stocks in this theme: 3696.HK, ARQT, HALO, OBIO, VCEL, WVE. See the constituent table for details.
